Treatment(s) already received-None Posts on Medivizor
Navigation Menu

Treatment(s) already received-None Posts on Medivizor

Evaluating PCR therapy for previously untreated indolent non-Hodgkin’s lymphoma

Posted by on Mar 31, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the long-term effectiveness and safety of a new chemotherapy regimen in patients with previously untreated indolent (painless) non-Hodgkin’s lymphoma (NHL). This study concluded that this regimen is effective and well-tolerated for these patients. Some background There are three common types of painless NHL....

Read More

Which treatment works best, nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone for advanced melanoma

Posted by on Nov 7, 2018 in Melanoma | 0 comments

In a nutshell This study wanted to find out which medications are better for treating advanced melanoma; nivolumab (Opdivo) plus ipilimumab (Yervoy), nivolumab alone, or ipilimumab alone. The study found that using the combination of nivolumab and ipilimumab was more effective than using nivolumab alone, with the least...

Read More

Comparing prostate surgery with radiotherapy and radiotherapy with androgen deprivation therapy for advanced prostate cancer

Posted by on Oct 28, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to investigate the long-term effects of two treatment combinations for advanced prostate cancer. This study found that surgery and radiotherapy had improved overall survival in comparison with radiotherapy plus androgen deprivation therapy (ADT) in these patients, but with higher rates of side-effects. Some background...

Read More

Is a low-intensity chemotherapy treatment plan safe and effective for elderly patients with Acute Myeloid Leukemia?

Posted by on Sep 6, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to create a safe and effective low-intensity chemotherapy treatment plan for elderly patients with AML . This is an ongoing clinical trial and so far the authors have found the therapy has been safe and effective. Some background Outcomes for elderly patients with AML in the past have not been good due to the high...

Read More

Evaluating the BR regimen in patients with low-tumor burden follicular lymphoma

Posted by on Sep 4, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of the BR regimen (rituximab, bendamustine) in elderly patients with untreated low-tumor burden follicular lymphoma (LTBFL). This study concluded that the BR regimen may provide positive outcomes for these patients. Some background Low-tumor burden follicular lymphoma (LTBFL) is a type of...

Read More

Is pirarubicin safer and more effective than doxorubicin in R-CHOP for diffuse large B-cell lymphoma?

Posted by on Jul 15, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared the safety and effectiveness of two first-line chemotherapy regimens for diffuse large B-cell lymphoma. This study concluded that the R-THP-COP regimen was as effective as conventional R-CHOP for diffuse large B-cell lymphoma. Some background R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine,...

Read More

Is pirarubicin safer and more effective than doxorubicin in R-CHOP for diffuse large B-cell lymphoma?

Posted by on Jul 15, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared the safety and effectiveness of two first-line chemotherapy regimens for diffuse large B-cell lymphoma. This study concluded that the R-THP-COP regimen was as effective as conventional R-CHOP for diffuse large B-cell lymphoma. Some background R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine,...

Read More

Which is more effective in secondary acute myeloid leukemia, FLAG or standard 7+3 induction therapy?

Posted by on Jul 3, 2018 in Leukemia | 0 comments

In a nutshell This study analyzed different types of induction chemotherapy regimes in secondary acute myeloid leukemia. The authors concluded that the FLAG combination had a high response rate and a low level of treatment-related side effects. Some background Secondary acute myeloid leukemia is a type of leukemia arising from a pre-existing...

Read More